Bismuth Nanoantibiotics Display Anticandidal Activity and Disrupt the Biofilm and Cell Morphology of the Emergent Pathogenic Yeast Candida auris.
Roberto Vazquez-MunozFernando D LopezJose L Lopez-RibotPublished in: Antibiotics (Basel, Switzerland) (2020)
Candida auris is an emergent multidrug-resistant pathogenic yeast, which forms biofilms resistant to antifungals, sanitizing procedures, and harsh environmental conditions. Antimicrobial nanomaterials represent an alternative to reduce the spread of pathogens-including yeasts-regardless of their drug-resistant profile. Here we have assessed the antimicrobial activity of easy-to-synthesize bismuth nanoparticles (BiNPs) against the emergent multidrug-resistant yeast Candida auris, under both planktonic and biofilm growing conditions. Additionally, we have examined the effect of these BiNPs on cell morphology and biofilm structure. Under planktonic conditions, BiNPs MIC values ranged from 1 to 4 µg mL-1 against multiple C. auris strains tested, including representatives of all different clades. Regarding the inhibition of biofilm formation, the calculated BiNPs IC50 values ranged from 5.1 to 113.1 µg mL-1. Scanning electron microscopy (SEM) observations indicated that BiNPs disrupted the C. auris cell morphology and the structure of the biofilms. In conclusion, BiNPs displayed strong antifungal activity against all strains of C. auris under planktonic conditions, but moderate activity against biofilm growth. BiNPs may potentially contribute to reducing the spread of C. auris strains at healthcare facilities, as sanitizers and future potential treatments. More research on the antimicrobial activity of BiNPs is warranted.
Keyphrases
- candida albicans
- biofilm formation
- multidrug resistant
- drug resistant
- pseudomonas aeruginosa
- staphylococcus aureus
- escherichia coli
- acinetobacter baumannii
- healthcare
- gram negative
- electron microscopy
- cell therapy
- saccharomyces cerevisiae
- klebsiella pneumoniae
- social media
- cystic fibrosis
- high intensity
- risk assessment
- current status
- cell wall
- antimicrobial resistance
- health insurance
- climate change